Thalidomide's second life in Indian leprosy
Wimmelbücker and Kar show India’s thalidomide path ran through leprosy NGOs and delayed state control, not the 1960s sleeping-pill market of Europe.
Source
A history of thalidomide in India
Study at a glance
- Design
- Qualitative / archival — Documentary reconstruction of thalidomide’s Indian path via leprosy NGOs and delayed regulation
- N
- Archival/clinical/press sources (Grünenthal trials, WHO leprosy files); not a primary sample N
- Population
- Thalidomide importation, ENL trials, and regulation in India from the 1960s onward
- Outcome
- India’s thalidomide history through leprosy treatment rather than a 1960s hypnotic mass market
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Thalidomide's second life in Indian leprosy
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Thalidomide has been prescribed for leprosy patients in India since 1966.
Thalidomide has been prescribed for leprosy patients in India since 1966 and gained increasing importance during the last twenty years as a therapeutic in the treatment of multiple myeloma
Most of about 5000 surviving recognised embryopathy babies were born in developed capitalist economies, nearly 3000 in West Germany.
Historical studies, however, largely adopted the national perspectives of those developed capitalist economies in which most of about 5000 surviving babies were born with prenatal damages that were officially recognized as thalidomide embryopathy, nearly 3000 of them in West Germany alone
What they did
The authors use Grünenthal trial documents, Israeli papers on Sheskin, WHO leprosy files, and published clinical and press sources—company archives still closed; Indian ministry and CLTRI holdings not then accessible—to track import, ENL trials after 1965, 1986 distribution responsibility, and 2002 approval for ENL and myeloma.
What they found
DCBL held Commonwealth rights including India, but the 1960s hypnotic market barely opened. After Sheskin, European mission doctors and WHO brought the drug for type-2 leprosy reactions in the country with the world’s largest leprosy population. Safety sat with doctors and the producer until 1986. No confirmed Indian embryopathy case is documented; surveillance remains weak as uses expand.
The limits
What it doesn't show
Closed company and ministry archives limit the record. The 5000/3000 birth-defect figures refer to recognised cases in rich countries, not India. Absence of confirmed Indian cases is not proof of zero harm.
Key terms
- Thalidomide embryopathy
- Birth defects from maternal intake roughly between days 20 and 36 of gestation.
- ENL / type 2 reaction
- Severe leprosy reaction for which thalidomide was reused from the mid-1960s.
- DCBL
- Distillers Company (Biochemicals) Limited, British licencee with Commonwealth sales rights including India.
- 1986 shift
- When the government of India began taking responsibility for distribution and adverse-effect monitoring.
Flashcards
0 of 11 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
India’s main historical use of thalidomide here is?
Common questions
Why little 1960 hypnotic use in India?
Late commercial interest plus a growing domestic industry and later patent-term limits reduced import openings.
How did the drug return?
As treatment for leprosy reactions, via NGOs, Sheskin’s report, Grünenthal supply, and WHO.
What is unfinished?
Implementing embryotoxic safety in a large diverse market, especially private-sector use after 2002.
More on Public health